Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Helm

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Minnesota Medicine|June 12, 2004
Basic immunology: a primerThomas Helm
Dermatology Online Journal|March 23, 2017
Mohs micrographic surgery and secondary intention healing of a plantar melanoma in-situJason Schoenfeld, Paul Wirth, Thomas Helm
Journal of Orthopaedics|March 26, 2019
Outcomes for cemented dual mobility cup to treat recurrent instability; A UK case seriesAndrew Neil Wheelton, Darren Myatt, Anthony Thomas Helm
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|March 30, 2012
Clinical stage of Merkel cell carcinoma and survival are not associated with Breslow thickness of biopsied tumorLeonid Izikson, Thomas Helm, Novie Sroa, et al.
Cutis|January 21, 2006
The vanishing biopsy: the trend toward smaller specimensEmmy M Fernandez, Thomas Helm, Michael Ioffreda, et al.
Journal of Drugs in Dermatology : JDD|July 11, 2003
Successful treatment of extramammary Paget's disease with imiquimodZheng Qian, Nathalie C Zeitoun, Sherry Shieh, et al.
International Journal of Clinical and Experimental Pathology|July 28, 2010
Correlating array comparative genomic hybridization findings with histology and outcome in spitzoid melanocytic neoplasmsLiaqat Ali, Thomas Helm, Richard Cheney, et al.
Human Pathology|December 25, 2014
Microvessel density, lymphovascular density, and lymphovascular invasion in primary cutaneous melanoma-correlation with histopathologic prognosticators and BRAF statusPhyu Phyu Aung, Dominick Leone, John Kyle Feller, et al.
The British Journal of Dermatology|November 25, 2023
Validation of epidermal AMBRA1 and loricrin (AMBLor) as a prognostic biomarker for nonulcerated American Joint Committee on Cancer stage I/II cutaneous melanomaTom Ewen, Akhtar Husain, Niki Stefanos, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Minnesota Medicine|June 12, 2004
Basic immunology: a primerThomas Helm
Dermatology Online Journal|March 23, 2017
Mohs micrographic surgery and secondary intention healing of a plantar melanoma in-situJason Schoenfeld, Paul Wirth, Thomas Helm
Journal of Orthopaedics|March 26, 2019
Outcomes for cemented dual mobility cup to treat recurrent instability; A UK case seriesAndrew Neil Wheelton, Darren Myatt, Anthony Thomas Helm
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|March 30, 2012
Clinical stage of Merkel cell carcinoma and survival are not associated with Breslow thickness of biopsied tumorLeonid Izikson, Thomas Helm, Novie Sroa, et al.
Cutis|January 21, 2006
The vanishing biopsy: the trend toward smaller specimensEmmy M Fernandez, Thomas Helm, Michael Ioffreda, et al.
Journal of Drugs in Dermatology : JDD|July 11, 2003
Successful treatment of extramammary Paget's disease with imiquimodZheng Qian, Nathalie C Zeitoun, Sherry Shieh, et al.
International Journal of Clinical and Experimental Pathology|July 28, 2010
Correlating array comparative genomic hybridization findings with histology and outcome in spitzoid melanocytic neoplasmsLiaqat Ali, Thomas Helm, Richard Cheney, et al.
Human Pathology|December 25, 2014
Microvessel density, lymphovascular density, and lymphovascular invasion in primary cutaneous melanoma-correlation with histopathologic prognosticators and BRAF statusPhyu Phyu Aung, Dominick Leone, John Kyle Feller, et al.
The British Journal of Dermatology|November 25, 2023
Validation of epidermal AMBRA1 and loricrin (AMBLor) as a prognostic biomarker for nonulcerated American Joint Committee on Cancer stage I/II cutaneous melanomaTom Ewen, Akhtar Husain, Niki Stefanos, et al.
Pageof 1